Recurrent Small Cell Lung Cancer
28
1
1
19
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
11 trials with published results (39%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
14.3%
4 terminated out of 28 trials
82.6%
-3.9% vs benchmark
0%
0 trials in Phase 3/4
58%
11 of 19 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 19 completed trials
Clinical Trials (28)
Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer
The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer
Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer
Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients
Anlotinib in Treatment of Recurrent Small Cell Lung Cancer
Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer
Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer
7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer
Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body
CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer
S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer
Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors
Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy
Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer